New York, USA - (June 4, 2024) - Sonio, the artificial intelligence company revolutionizing fetal ultrasound reporting, announced today that the second version of their AI product, Sonio Detect, has officially been FDA cleared.

Sonio Detect AI is designed to ensure high-quality exams, automatically detecting views, anatomical structures, and verifying quality criteria of ultrasound images.

The latest version of Sonio Detect poses several new capabilities:

- A reliable ability to recognize fetal ultrasound views: it detects T1 views with 91,4% sensitivity and T2/T3 views with 93,7% sensitivity.

- Enables automatic extraction of complex views (heart/brain) from clips to reduce complexity and tediousness for sonographers: up to 10 min saved on complex exams*.

- 60 % of ISUOG and 63% of AIUM detailed exam protocols possible without manual annotation, with a roadmap set to cover 100% by next release.

- It detects brain structures with 93,4% sensitivity and 94,9% specificity as well as heart and thorax structures with 91,9% sensitivity and 97,6% specificity in the second and third trimester**. Sonio also automatically detects structures of placenta and CRL/NT and automatically detects placenta location and fetus sex, (see details in 510 K summary)

The value of the Sonio solution lies in the combination of modern, state-of-the-art IT infrastructure technology, backed by AI-enhanced clinical outcomes, to streamline workflows and bring efficiencies for healthcare professionals.

Sonio ultrasound reporting solution implements the latest IT infrastructure technologies and adheres to stringent security standards, such as HIPAA compliance and encryption protocols, to safeguard sensitive medical information and mitigate the risk of data breaches. It also enables OB GYN professionals to review, in a secure manner, images and reports remotely. This flexibility not only enhances clinical efficiency but also empowers practitioners to provide timely consultations and second opinions.

Sonio Cloud reporting software continually & seamlessly updates and improves the platform to incorporate the latest advancements in imaging technology, AI algorithms, and clinical decision support systems.

“We’re excited to reach this new milestone in Sonio’s launch in the US Market,” says Cecile Brosset, CEO of Sonio. “Alongside our adoption in multiple hospitals across the US this year, we are proud to continue successfully expanding within the US provider market with this additional clearance.”

Ultrasound reporting software could be a turning point for OBGYN practices, offering a myriad of benefits that elevate clinical care, streamline workflows, and improve patient outcomes. By harnessing the power of advanced imaging technology and intuitive software solutions, OBGYN professionals can enhance diagnostic accuracy, optimize practice efficiency, and deliver exceptional patient care, ensuring a brighter and healthier future for women's health.

With Sonio's advanced ultrasound reporting software, healthcare providers gain access to powerful tools and features that could enhance screening accuracy. From customizable protocols and finding-based reporting templates to clinical decision support features powered by artificial intelligence (AI), the software empowers clinicians to make informed treatment decisions with confidence.

Sonio Ultrasound reporting software streamlines workflows by automating repetitive tasks, such as data entry and report generation, which could free up valuable time for healthcare professionals to focus on patient care.

Sonio’s ambition is to bridge the gap between structure, view detection and anomaly detection to improve both screening and diagnosis in the near future.


About Sonio:
Sonio is a highly customizable reporting solution powered by AI for automation, efficiency and quality control. Sonio is based on over five years of research and collaboration between leading experts in fetal medicine and AI.